Drug Profile
Research programme: recombinant Dengue virus vaccine - Center for Genetic Engineering and Biotechnology
Alternative Names: Dengue virus vaccine - Center for Genetic Engineering and BiotechnologyLatest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Class Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Dengue
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in Dengue(Prevention) in Cuba (Parenteral)
- 31 Dec 2015 Research programme: recombinant Dengue virus vaccine - Center for Genetic Engineering and Biotechnology is available for licensing as of 31 Dec 2015. http://gndp.cigb.edu.cu
- 31 Dec 2015 Preclinical trials in Dengue (Prevention) in Cuba (Parenteral) before December 2015